证券代码：002198 证券简称：嘉应制药 公告编号：2023-027 广东嘉应制药股份有限公司 第六届监事会第六次会议决议公告 第六届监事会第六次会议决议公告 4、会议的召集、召开符合法律、法规及公司章程的规定，表决形成的决议 合法、有效。 二、监事会会议审议情况 会议以投票表决方式通过了以下议案： 1、会议以 3 票同意，0票反对，0票弃权审议通过了《关于公司<2023年半 年度报告>及<2023年半年度报告摘要>的议案》； 经审核，监事会认为董事会编制和审核公司《2023 年半年度报告》全文及 摘要的程序符合法律、法规和中国证监会的规定，报告内容真实、准确、完整地 反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本公司及全体监事会成员保证本公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"）第六届监事会第六次 会议通知已于2023年8月15日分别以专人送达、电子邮件或传真等方式送达公司 全体监事。2023年8月25日，会议如期以现场方式举行。 2、会议应到监事3名，实到监事3名。 3、经全 ...

上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：广东嘉应制药股份有限公司 金额单位：人民币元 | | | 占用方与上 | 上市公司核 | | 报告期占用累计发生 | 报告期占用 | 报告期偿还累计发 | | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 期初占用资金余额 | 金额（不含利息） | 资金的利息 | 生额 | 期末占用资金余额 | 原因 | 占用性质 | | | | 联关系 | 目 | | | （如有） | | | | | | | | | | | | | | | | 非经营性 | | | | | | | | | | | | 占用 | | 现大股东及其附属企业 | | | | | | | | | | 非经营性 | | | | | | | | | | | | 占用 | | 小 计 | —— | —— | —— | —— | —— | —— | —— | —— | —— | —— | ...

（一）关于关联方资金占用情况的专项说明和独立意见 报告期内，公司不存在控股股东及其他关联方非经营性占用公司资金的情况，也 不存在以前年度发生并累计至2023年6月30日的违规关联方占用资金情况。 广东嘉应制药股份有限公司独立董事 对第六届董事会第六次会议相关事项的独立意见 广东嘉应制药股份有限公司（以下简称"公司"）第六届董事会第六次会议于2023 年8月25日以现场结合视频和邮件通讯方式召开，公司独立董事郭华平、徐驰、张富 明就报告期相关事项发表了如下专项说明和独立意见： 关于关联方资金往来和对外担保情况的专项说明和独立意见 按照中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担保 的监管要求》的要求，本人作为广东嘉应制药股份有限公司的独立董事，通过对公司 2023年上半年关联方资金占用和对外担保情况进行认真地了解和核查，发表独立意见 如下： 2、截至2023年6月30日，公司不存在为控股股东及本公司持股50％以下的其他关 联方、任何非法人单位或个人提供担保的情形，也不存在违规对外担保情况。 3、公司制定了《对外担保管理制度》，规定了对外担保的审批权限、决策程序 和有关的风险控制措施，并严格 ...

第六届董事会第六次会议决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2023-026 第六届董事会第六次会议决议公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"） 第六届董事会第六次 会议通知已于 2023 年 8 月 15 日以专人送达、电子邮件和电话等方式送达全体董 事、监事及高级管理人员。2023 年 8 月 25 日，会议如期以现场结合视频和邮件 通讯方式举行。 2、会议应出席董事 9 人，实际出席董事 9 人，董事朱拉伊、郭华平、张富 明以通讯方式出席。 3、公司监事会成员和高级管理人员列席了会议。因个人工作安排原因，董 事长朱拉伊先生未能现场参会，会议由副董事长黄晓亮先生主持。 4、会议的召集、召开符合法律、法规及公司章程的规定，表决形成的决议 合法、有效。 二、董事会会议审议情况 广东嘉应制药股份有限公司 第六届董事会第六次会议决议公告 公司《2023 年半年度报告全文》（公告编号：2023-024）详见指定信息披 露媒体巨潮资讯网（www.cninf ...

证券代码：002198 证券简称：嘉应制药 广东嘉应制药股份有限公司 投资者关系活动记录表 编号：2023-015 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 参加嘉应制药 2022 年度业绩网上说明会的投资者 时间 2023 年 5 月 10 日 15:00-17:00 地点 "全景•路演天下"（http://rs.p5w.net） "东方财富路演" （https://roadshow.eastmoney.com/） 上市公司 接待人员姓名 朱拉伊 董事长 黄晓亮 副董事长兼董秘 郭华平 独立董事 冯杰 财务总监 投资者关系活动 主要内容介绍 1、公司在以您为核心的董事会的努力下，取得了靓丽的业绩。 感谢您和董事会。希望您能继续带领公司走向更加辉煌的明天！ 答：尊敬的投资者，您好！非常感谢您的支持和对公司的美 好祝愿，新的一年公司将继往开来，在董事会及公司管理层的带 领下，以"以德正心、嘉惠于民"的理念，破难攻坚，踔厉奋发， 笃定前行，推动公司发展迈上新台阶，希望您能继续关注和支持 我们公司。 2、公司 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 128,497,088.51, representing a 6.56% increase compared to CNY 120,586,266.19 in the same period last year[5] - Net profit attributable to shareholders increased by 380.58% to CNY 12,185,969.05 from CNY 2,535,662.28 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 11,019,022.44, up 310.95% from CNY 2,681,378.06 in the previous year[5] - Basic and diluted earnings per share rose to CNY 0.0240, a 380.00% increase from CNY 0.0050 in the same quarter last year[5] - Total operating revenue for Q1 2023 was CNY 128,497,088.51, an increase of 6.9% compared to CNY 120,586,266.19 in Q1 2022[16] - Operating profit for Q1 2023 reached CNY 13,120,025.47, significantly up from CNY 3,888,881.56 in the same period last year, marking an increase of 237.5%[18] - Net profit attributable to the parent company was CNY 12,185,969.05, compared to CNY 2,535,662.28 in Q1 2022, representing a growth of 380.5%[19] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.0240, up from CNY 0.0050 in Q1 2022[19] Assets and Liabilities - Total assets decreased by 1.83% to CNY 831,190,971.73 from CNY 846,650,977.26 at the end of the previous year[5] - The company's total assets as of March 31, 2023, amount to CNY 831,190,971.73, down from CNY 846,650,977.26 at the beginning of the year[14] - The total current assets decreased to CNY 548,050,880.96 from CNY 557,432,509.74[13] - The total non-current assets decreased to CNY 283,140,090.77 from CNY 289,218,467.52[14] - The total current liabilities decreased to CNY 55,332,590.34 from CNY 82,947,126.75[14] - The total non-current liabilities remained relatively stable at CNY 35,254,397.84 compared to CNY 35,285,836.01 at the beginning of the year[14] - Total liabilities decreased to CNY 90,586,988.18 from CNY 118,232,962.76 year-over-year[18] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 956,929.25, a decline of 187.25% compared to a net inflow of CNY 1,096,710.93 in the previous year[5] - Cash flow from operating activities showed a net outflow of CNY -956,929.25, a decrease from a net inflow of CNY 1,096,710.93 in the previous year[19] - The net cash flow from investment activities was -937,382.74 CNY, indicating a decrease compared to the previous quarter[20] - The total cash outflow from investment activities amounted to 51,324,780.00 CNY, with 50,000,000.00 CNY related to other investment activities[20] - The net cash flow from financing activities was -10,361,477.89 CNY, primarily due to debt repayment and dividend distributions[20] - The company reported a net decrease in cash and cash equivalents of 1,894,311.99 CNY for the quarter[20] - Cash and cash equivalents at the end of the reporting period are CNY 181,963,721.91, slightly down from CNY 183,858,033.90[13] Other Income and Expenses - The company received government subsidies amounting to CNY 1,378,263.01, contributing to a significant increase in other income by 8185.69%[8] - Other income increased to CNY 1,386,076.13 from CNY 16,728.56 in the previous year, indicating a significant rise in additional revenue sources[16] - The company reported a decrease in total operating costs to CNY 115,949,772.87 from CNY 116,699,221.13 in the previous year[16] - Research and development expenses were CNY 1,657,099.81, slightly down from CNY 1,737,267.90 in Q1 2022[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,688[10] - The top 10 shareholders hold a total of 11.27% (57,200,000 shares) by Dongfang Securities Co., Ltd.[10] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[20]

Financial Performance - The company's operating revenue for 2022 was CNY 659,195,732.41, representing a 14.70% increase compared to CNY 574,713,387.08 in 2021[20]. - Net profit attributable to shareholders reached CNY 43,934,703.72, a significant increase of 2,874.05% from CNY 1,477,269.72 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 43,973,457.47, up 15,489.86% from CNY 282,064.41 in 2021[20]. - Basic earnings per share rose to CNY 0.0866, a 2,886.21% increase from CNY 0.0029 in 2021[20]. - Total assets at the end of 2022 were CNY 846,650,977.26, reflecting a 4.87% increase from CNY 807,337,692.89 at the end of 2021[20]. - The company's net assets attributable to shareholders increased by 6.42% to CNY 728,418,014.50 from CNY 684,483,310.78 in 2021[20]. - The net cash flow from operating activities decreased by 47.58% to CNY 27,154,401.73 from CNY 51,800,132.35 in the previous year[20]. - The company achieved total revenue of ¥659,195,732.41 in 2022, representing a year-on-year growth of 14.70%[77]. - Net profit for the year was ¥43,934,703.72, showing a significant increase of 2,874.05% compared to the previous year[77]. - The company generated a net cash flow from operating activities of ¥27,154,401.73[77]. Market and Industry Trends - The overall pharmaceutical industry in China saw a decline in revenue by 1.6% in 2022, while the traditional Chinese medicine sector experienced a revenue growth of 5.6%[36]. - The total healthcare expenditure in China reached CNY 75,593.6 billion in 2021, with a year-on-year growth of 9.82%[33]. - By the end of 2022, the number of people covered by basic medical insurance in China was approximately 1.35 billion, maintaining a coverage rate of over 95%[35]. - The pharmaceutical industry in China is characterized by strong demand due to factors such as economic growth, population aging, and expanded medical insurance coverage[43]. - The aging population in China is increasing, with 264 million people aged 60 and above, representing a 42.7% growth since 2010, creating a significant demand for healthcare services[60]. Research and Development - The company has focused on the research and development of traditional Chinese medicine products, aligning with national health policies promoting traditional medicine[30]. - The R&D expenses of A-share listed companies before 2017 reached CNY 6.151 billion in the first three quarters of 2022, with a year-on-year growth of 12.67%[41]. - The R&D expense ratio for these companies was 2.46% in 2022, indicating a continuous increase in R&D investment intensity[41]. - The company applied for and obtained 3 new utility model patents in 2022 to support its research and development efforts[84]. - The company completed major R&D projects, including the development of the "Jiegu" series products, aimed at enhancing market share and clinical precision[95]. Regulatory Environment - The management highlighted potential risks including industry policy changes and concentrated leading products[3]. - The company plans to enhance its quality control and management practices in response to regulatory changes aimed at ensuring drug safety and quality[58]. - The State Administration for Market Regulation has introduced a new classification for TCM registration, focusing on innovative and improved TCM products[54]. - The company is closely monitoring national policy directions and enhancing internal management to improve operational efficiency and resilience against policy risks[122]. Corporate Governance - The company has no controlling shareholder and operates independently in terms of business, personnel, assets, and finance[134]. - The board of directors consists of 7 members, including 3 independent directors, which complies with legal and regulatory requirements[135]. - The company has established a performance evaluation and incentive mechanism for its directors and senior management, ensuring transparency in appointments[137]. - The company respects and protects the rights of stakeholders, aiming for a balance of interests among all parties involved[139]. - The company has implemented various communication channels with shareholders, including phone calls and online meetings[133]. Environmental Responsibility - The company adheres to multiple environmental protection laws and industry standards, including the GB37823-2019 for air pollutants[182]. - The total emissions of nitrogen oxides from the company are within the limit of 150 mg/m³, with actual emissions recorded at 52-60 mg/m³[185]. - The company has a centralized wastewater discharge system with no reported exceedances in discharge standards[185]. - The company has increased its investment in environmental protection, focusing on wastewater and solid waste treatment, as well as maintenance and upgrades of pollution control facilities[194][195]. Employee Welfare and Management - The total number of employees at the end of the reporting period is 732, with 381 in the parent company and 351 in major subsidiaries[167]. - The company emphasizes employee training, focusing on enhancing overall capabilities and specific skills for middle and senior management[170]. - The company conducts regular health check-ups for workshop employees and provides necessary labor protection supplies and training to enhance safety awareness[199]. - The company has established a system for employee rights protection, including a workers' representative assembly to address issues related to wages, benefits, and labor safety[199].

关于举行 2022 年度网上业绩说明会并征集相关问题的公告 证券代码：002198 证券简称：嘉应制药 公告编号：2023-013 广东嘉应制药股份有限公司 关于举行 2022 年度网上业绩说明会并征集相关问题的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）《2022年年度报告》全文 及其摘要于2023年4月28日经公司第六届董事会第五次会议审议通过。本公司 《 2022 年 年 度 报 告 全 文 》 已 于 2023 年 4 月 29 日 刊 登 在 巨 潮 资 讯 网 站 （http://www.cninfo.com.cn）上，《2022年年度报告摘要》刊登在当日的《证 券 时 报 》 、 《 中 国 证 券 报 》 、 《 证 券 日 报 》 和 巨 潮 资 讯 网 站 （http://www.cninfo.com.cn）上，供全体股东和投资者查阅。 为使广大投资者进一步详细了解公司年报信息，公司将于2023年5月10日星 期三15:00-17:00，在全景网举行2022年度业绩网上说明会。 一、业 ...

Group 1: Natural Borneol Project - The purity of the company's natural borneol extraction ranges between 96% and 99%, with market prices for 96% purity around 3000 to 5000 RMB per kilogram [2][3] - The company has established pilot production lines for extraction and purification, which have been operational for over 2 years, with an expected annual capacity of 250 tons post-completion of facilities [3][4] - The domestic market demand for natural right-handed borneol is approximately 650 tons per year, while international demand is about 10,500 tons per year, indicating a significant market opportunity due to supply shortages [4][5] Group 2: Company Performance - The company's revenue for the first three quarters of the year reached 395 million RMB, with a net profit of 68 million RMB, reflecting a year-on-year growth of 325.29% [5][6] - The expected net profit for the entire year is projected to be between 68 million and 73 million RMB [5][6] - The subsidiary, Jinsan Pharmaceutical, is expected to achieve a net profit of 58.25 million RMB as per the profit compensation agreement [6][7] Group 3: Investment and Market Strategy - The company plans to focus future investments on the traditional Chinese medicine sector, emphasizing profitability in potential investments [7][8] - There is currently no intention to acquire hospitals or traditional Chinese medicine enterprises [7][8] - The company aims to enhance its market share and brand through increased advertising and sales team expansion, while also exploring external investments to improve overall profitability [8]

Group 1: Company Operations - The management structure of the company is stable, and the operational situation is normal [1] - Tiger Hui is not currently involved in the actual operations of the company, and there are no significant disagreements between the management and Tiger Hui [2] Group 2: Production and Capacity - The company’s subsidiary, Huqingyuan Bio, is expanding the cultivation of the Mei tree as planned, with natural borne ice currently in small-scale trial production [2] - The company is optimistic about the development prospects of the Mei tree industry, believing it will contribute to future performance [2] - The fundraising projects from the IPO, including the production of dual-purpose throat wind powder and solid essence ginseng pills, have been completed, with capacity utilization reaching approximately 100% [2] Group 3: Research and Development - The company’s new drugs, including diabetes and anti-tumor medications, are in different stages of development, with diabetes drugs in clinical stages and anti-tumor drugs in preclinical research [3] - The company will disclose any new developments in drug research in accordance with regulations [3] Group 4: Shareholder Actions - The company acknowledges that shareholders may reduce their holdings for personal financing or lifestyle improvements, complying with legal and regulatory requirements for information disclosure [3]